Document is current
Any future updates will be listed below
-
Authors
Sisic, Leila
Crnovrsanin, Nerma
Nienhueser, Henrik
Jung, Jin-On
Schiefer, Sabine
Haag, Georg Martin
Bruckner, Thomas
Schneider, Martin
Müller-Stich, Beat P.
Büchler, Markus W.
Schmidt, Thomas
-
Funding
Funding for this research was provided by:
Nordic Pharma Group
Taiho Pharmaceutical
Medizinische Fakultät Heidelberg der Universität Heidelberg
- License Information
-
More Information
Article History
Received: 7 July 2022
Accepted: 26 January 2023
First Online: 10 February 2023
Declarations
:
: The authors declare no competing interests.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients for being included in the study.
: The authors declare that they do not have any commercial interest in the subject of study.The authors did not receive financial support or funding for conduction of this study.GM Haag reports fees for advisory role from Sanofi, Roche, Taiho, Nordic, Lilly, Pfizer, honoraria from Roche, travel grants from Amgen, Ipsen and Celgene; research funding is provided by Nordic and Taiho Pharmaceuticals. There is no relationship to the submitted work.
